REDUCED OR ELIMINATED OCS USE WHILE
SIMULTANEOUSLY IMPROVING ASTHMA CONTROL

OCS dose reduction at Week 24 in the ITT population (primary endpoint)1,2,a-c

86%
OF PATIENTS
Reduced or eliminated their ocs dose
at Week 24 with DUPIXENT 300 mg + SOC (n=103)
vs 68% with placebo + SOC (n=107) (Trial 3)2
  • 70% reduction in OCS dose (median 100%) from baseline at Week 24 with DUPIXENT 300 mg + SOC (n=103) (95% CI: 60%, 80%) vs 42% (median 50%) with placebo + SOC (n=107) (Trial 3, primary endpoint)1
  • 52% of patients completely eliminated OCS use at Week 24 with DUPIXENT 300 mg + SOC (n=103) vs 29% with placebo + SOC (n=107) (Trial 3, primary endpoint)1

DUPIXENT is the only biologic indicated for an OCS-dependent asthma population

59%
reduction IN ANNUALIZED RATE
OF SEVERE EXACERBATIONS

with DUPIXENT 300 mg + SOC (n=103)
vs placebo + SOC (n=107) (0.65 vs 1.60;
rate ratio: 0.41 [95% CI: 0.26, 0.63])
(Trial 3, secondary endpoint)1,a-d
220mL
improvement IN
PRE-BRONCHODILATOR FEV1

with DUPIXENT 300 mg + SOC (n=103)
vs 10 mL with placebo + SOC (n=107)
(LSM difference: 220 mL [95% CI: 90, 340 mL])
(Trial 3, secondary endpoint)2,a,b,d

  • Effects on lung function and on oral steroid and exacerbation reduction were similar irrespective of baseline blood eosinophil levels1
99.9% OF INSURANCE PLANS REQUIRE NO BIOMARKER TESTING FOR OCS-DEPENDENT ASTHMA PATIENTS ON DUPIXENT3
  • a ITT population was unrestricted by minimum baseline eosinophils or other Type 2 biomarkers (eg, FeNO or IgE).2
  • b The baseline mean OCS dose was 12 mg in the placebo group and 11 mg in the group receiving DUPIXENT.1
  • c For inclusion in the study, all patients were required to be on daily OCS in addition to regular use of standard of care of high-dose ICS plus an additional controller medication; subjects with baseline blood eosinophil levels >1500 cells/μL (<1.3%) were excluded.1
  • d Asthma exacerbation was defined as a temporary increase in OCS dose for at least 3 days.1

ICS, inhaled corticosteroid.

See an OCS-dependent patient appropriate for DUPIXENT

VIEW PATIENT

References:

  1. DUPIXENT Prescribing Information.
  2. Rabe KF, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378(26):2475-2485.
  3. UnitedHealthcare. UnitedHealthcare Pharmacy Clinical Pharmacy Programs. 2019.